CoChat
Sign Up
Cited by 101Medication Adherence and ComplianceAttention Deficit Hyperactivity DisorderPharmaceutical studies and practices

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Assessment of Adherence Measures with Different Stimulants Among Children and Adolescents

Sanchez, Robert J., Crismon, M. Lynn, Barner, Jamie C., Bettinger, Tawny, Wilson, James P.·2005·Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
DOI 10.1592/phco.2005.25.7.909
Open this paper in CoChat — free account

Abstract

Study Objective. To examine adherence measures with different stimulants in children and adolescents. Design. Retrospective analysis. Data Source. Texas Medicaid prescription claims database. Patients. A total of 9549 patients aged 5–18 years with attention‐deficit—hyperactivity disorder. Measurements and Main Results. Paid prescription claims for newly started stimulants during the 2001–2002 school year were extracted from a database; 28,344 prescriptions (9549 patients) were available for analysis. Adherence was evaluated based on the drug therapy prescribed (i.e., mixed amphetamine salts, immediate‐release methylphenidate, and extended‐release methylphenidate—OROS [oral‐osmotic formulation]) and the age and sex of the patient. Adherence measures were persistence and medication possession ratio (MPR). Persistence was higher for extended‐release methylphenidate—OROS (0.50 ± 0.33) than for mixed amphetamine salts (0.42 ± 0.29) or immediate‐release methylphenidate (0.37 ± 0.26; p<0.001). The MPR was also higher for extended‐release methylphenidate—OROS (0.76 ± 0.37) than for mixed amphetamine salts (0.73 ± 0.37) or immediate‐release methylphenidate (0.69 ± 0.37; p<0.001). Patients aged 5–9 years had equal or better persistence and MPR than those aged 10–14 and 15–18 years (p<0.001). No sex‐related differences in adherence were observed. Conclusion. Adherence measures in our study were low. Although they were significantly better for extended‐release methylphenidate—OROS than the other stimulants, the clinical significance of these differences are unclear. Further research should be conducted regarding pharmaceutical products, administration methods, and clinical interventions that may enhance adherence.

Overview

Integrity signals

Registry

Crossref · 10.1592/phco.2005.25.7.909

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. American Psychiatric Association., 1994, Diagnostic and statistical manual for mental disorders
  2. Tebbi CK., 1993, Treatment compliance in childhood and adolescence, Cancer, 71, 441
  3. Fine S, 2001, Issues in medication adherence for children and adolescents with attention deficit hyperactivity disorder, B C Med J, 43, 277
  4. American Psychiatric Association., 1987, Diagnostic and statistical manual for mental disorders

Cited by

Sorted by citations

See all 101

Related

See all

Metadata

Authors
Sanchez, R. J., Crismon, M. L., Barner, J. C., Bettinger, T., & Wilson, J. P.
Affiliations
  • Texas Department of State Health Services (US)
  • Pfizer (United States) (US)
  • The University of Texas at Austin (US)
Corresponding author
Crismon, M. Lynn
ORCID
Venue
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher
Wiley
Published
2005-07
Volume
25
Issue
7
Pages
909-917
ISSN
  • 0277-0008 (ISSN-L)
  • 1875-9114
DOI
10.1592/phco.2005.25.7.909
OpenAlex
W2097767249
Cited by
101
References
50
Citations by year
2026: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 9 · 2013: 4 · 2012: 10
FWCI
4.49
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2390 d)
Locations
  • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
Texas Department of State Health Services
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
medication adherence, attention deficit hyperactivity disorder, stimulant medication, extended-release methylphenidate, mixed amphetamine salts, immediate-release methylphenidate, medication possession ratio, persistence, children and adolescents
MeSH terms
Adolescent, Amphetamines, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Child, Preschool, Delayed-Action Preparations, Female, Humans, Male, Methylphenidate, Patient Compliance, Retrospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review